[{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$9.0 million","newsHeadline":"Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"iX Biopharma"},{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital Singapore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroAiD(TM)II Holds Promise as a Safe Add-on Therapy to Standard Alzheimer Disease Symptomatic Treatments and May Have a Disease Modifying Effect by Delaying Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Moleac"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.
Lead Product(s):
MLC901
Therapeutic Area:NeurologyProduct Name: NeuroAiD II
Highest Development Status:Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator:
National University Hospital Singapore
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Under the agreement with Seelos Therapeutics, has acquired a worldwide license from iX Biopharma for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a technology known as WaferiX™.